Company Overview and News


Add LLY
to your dashboard

Headline News

Top Analyst Upgrades and Downgrades: Amazon, Boeing, Chesapeake Energy, Eli Lilly, Gilead, Micron, NVIDIA, P&G, Qualcomm and Many More

2018-01-16 247wallst
Stocks were indicated higher on Tuesday morning, for basically more of the same in gains almost every day of the new year. Now that the bull market is nearly nine years old, investors are deciding how to position their portfolios for 2018 and beyond. Investors are also looking for new ideas to generate income and gains. (498-0)

Incyte: Low Expectations, Great Growth, Looks Appealing

2018-01-12 seekingalpha
The combination of rapid growth and a 40% pullback from 2017 highs creates sales multiples that have collapsed. (13-0)

Nektar Therapeutics: Continued Upside In 2018

2018-01-12 seekingalpha
For the 214 program, I look forward to results from the PROPEL and PIVOT trials along with an investigator sponsored study in sarcoma. (8-0)

The Slow Push Upward Continues for Johnson & Johnson Stock

2018-01-05 investorplace
Johnson & Johnson (NYSE:JNJ) has remained a long-time favorite among conservative investors. Its production of necessary, recession-proof products as well as its consistent dividend have provided comfortable, consistent profits for decades. A large increase in 2017 has taken the healthcare giant to an average valuation. However, given the high earnings growth, JNJ stock remains well-positioned to continue its march higher. (10-0)

Stocks To Watch: Automakers Rev Up For 2018

2017-12-31 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn on the e-mail alert on to receive this article in your inbox every Saturday morning. (629-3)

More and More Short Sellers Raising the Stakes in Major Pharma

2017-12-28 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside. (222-1)

Hutchison China Meditech: Outlook For 2018

2017-12-21 seekingalpha
Shares have risen by 175% since my initial article and by 70% since my update piece.

Radius Health to Get Third Day-180 List of Outstanding Issues

2017-12-18 zacks
Radius Health, Inc. (RDUS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) will provide a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. (130-1)

MannKind: The Postmortem Is Available

2017-12-18 seekingalpha
With no positive trajectory, no incredible opportunity, and no significant growth tells the story of MannKind's future. (75-0)

Week In Review: Fosun Signs $125 Million Deal For Ardelyx IBS Treatment

2017-12-17 seekingalpha
Fosun Pharma (SHA: 600196; HK: 2196) obtained China rights to tenapanor, an Ardelyx (NASDAQ:ARDX) treatment for irritable bowel syndrome with constipation (IBS-C), in a $125 million agreement. Tenapanor is also expected to treat hyperphosphatemia related to chronic kidney disease. Ardelyx, a San Francisco area company, has completed US Phase III trials in which tenapanor met efficacy endpoints in both indications. (23-0)

7 A-Rated Healthcare Stocks to Buy | InvestorPlace

2017-12-15 investorplace
It’s the end of 2017, which means another tax year is about to end. For investors that means a few things. (37-0)

Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

2017-12-13 zacks
Intersect ENT, Inc. (XENT - Free Report) received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients. (66-0)

Short Sellers Can’t Make Up Their Minds on Major Pharma

2017-12-12 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside. (222-1)

BRIEF-Lilly's Cyramza meets Primary Endpoint in gastric cancer study

2017-12-08 reuters
* LILLY REPORTS TOP-LINE RESULTS FROM CYRAMZA® (RAMUCIRUMAB) PHASE 3 STUDY IN FIRST-LINE ADVANCED GASTRIC CANCER (2-0)

Solid Quant Score Keep Eli Lilly (LLY) a Buy

2017-12-08 investorplace
Eli Lilly and Company (NYSE:LLY) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking LLY has had from Portfolio Grader for the last month.

CUSIP: 532457108